OPTMLPeptide LibraryBack to the library

OPTML / THE CLEARER PICTURE

What changed. And why.

A visible record of editorial and product changes. Dates below describe work performed, not a promise of daily monitoring.

2026-11-02 / CLARITY UPDATE

Understand the evidence before the claim.

These changes reorganize the existing cited findings. They do not claim new medical review or refresh older source-check dates.

2026-11-02 / CONTENT COMPLETION

150 unique entries, with explicit boundaries.

The supplied spreadsheet contained 152 rows and 150 unique names; Tesamorelin and Trofinetide were duplicated. The library includes a written explanation for each unique entry, including product-label, identity-boundary, registry-only and evidence-gap guides.

Selected trial findings include negative endpoints and subgroup limitations. Bibliographic records are separate from appraised findings; unselected supplied links are excluded from public claim bibliographies.

Scope still matters.

This is not a worldwide inventory of every peptide, a systematic review of every claim, or a clinician-approved treatment directory. Read each guide’s source-check date and limitations.

How we check sources